Table 1

Baseline characteristics of trial populations

Semaglutide 1.0 mg (n = 404)Exenatide ER 2.0 mg (n = 405)Total (n = 809)
Age, years (min.–max.)56.4 (20–82)56.7 (21–83)56.6 (20–83)
HbA1c
 % (min.–max.)*8.4 (6.7–11.1)8.3 (6.5–11.2)8.3 (6.5–11.2)
 mmol/mol (min.–max.)67.9 (49.7–97.8)67.6 (47.5–98.9)67.7 (47.5–98.9)
Diabetes duration, years (min.–max.)9.0 (0.4–37.1)9.4 (0.3–54.0)9.2 (0.3–54.0)
Body weight, kg (min.–max.)96.2 (49.9–198.3)95.4 (53.2–171.9)95.8 (49.9–198.3)
BMI, (kg/m2) (min.–max.)34.0 (21.0–72.8)33.6 (21.2–55.8)33.8 (21.1–72.8)
eGFR (MDRD), mL/min/1.73 m2 (min.–max.)100.5 (60.0–208.0)100.5 (60.0–194.0)100.5 (60.0–208.0)
Sex, n (%)
 Female185 (45.8)177 (43.7)362 (44.7)
 Male219 (54.2)228 (56.3)447 (55.3)
Ethnicity, n (%)
 Hispanic or Latino91 (22.5)106 (26.2)197 (24.4)
 Not Hispanic or Latino313 (77.5)299 (73.8)612 (75.6)
Race, n (%)
 White341 (84.4)338 (83.5)679 (83.9)
 Black or African American28 (6.9)30 (7.4)58 (7.2)
 Asian8 (2.0)6 (1.5)14 (1.7)
 Other27 (6.6)31 (7.6)58 (7.2)
Diabetes medications at screening, n (%)
 Biguanides391 (96.8)390 (96.3)781 (96.5)
 Sulfonylureas181 (44.8)208 (51.4)389 (48.1)
 Thiazolidinediones13 (3.2)6 (1.5)19 (2.3)
 Other BG-lowering drugs (excluding insulin)1 (0.2)2 (0.5)3 (0.4)
 Long-acting insulins and analogs for injection0 (0)1 (0.2)1 (0.1)
  • Values are arithmetic means (minimum–maximum) or n (%). eGFR, estimated glomerular filtration rate.

  • *Min./max. HbA1c may be outside the range specified in the inclusion criteria because measurements were taken at the randomization visit.

  • †Subjects receiving other BG-lowering drugs, insulins, and analogs for injection were randomized in error.